BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 4, 2002
View Archived Issues
ZymoGenetics Raises $120M In Year’s First Biotech IPO
Read More
Discovering Relaxin Hormone’s Two Too-Long-AWOL Receptors Renews Interest In Its Roles
Read More
Pozen Starts Phase III Of MT 300 For Treating Severe Migraine
Read More
Biogen, Genaissance Align In Pharmacogenomics Area
Read More
Chiron Licenses TB Product To Public-Private Partnership
Read More
Other News To Note
Read More
Amgen Gains Quick Approval For Next-Generation Neupogen
Following swift approval from the FDA, Amgen Inc. expects its next blockbuster drug for chemotherapy patients to enter the market April 1. (BioWorld Today)
Read More